GSK

Sitryx announces collaboration partner Lilly has commenced a Phase 1 study of SIT-011 for chronic autoimmune and inflammatory diseases

Retrieved on: 
Thursday, January 4, 2024

Oxford, UK – 4 January 2024 – Sitryx Therapeutics (“the Company”), a biopharmaceutical company focused on regulating cell metabolism to develop disease-modifying therapeutics for chronic autoimmune and inflammatory diseases, today announces that Eli Lilly & Company (Lilly) has commenced a Phase 1 first-in-human study of SIT-011, a post-translational modification modulator program for chronic autoimmune and inflammatory diseases.

Key Points: 
  • Oxford, UK – 4 January 2024 – Sitryx Therapeutics (“the Company”), a biopharmaceutical company focused on regulating cell metabolism to develop disease-modifying therapeutics for chronic autoimmune and inflammatory diseases, today announces that Eli Lilly & Company (Lilly) has commenced a Phase 1 first-in-human study of SIT-011, a post-translational modification modulator program for chronic autoimmune and inflammatory diseases.
  • Lilly is leading further development and potential commercialization of the Phase 1 immunometabolism-targeting therapy.
  • Sitryx and Lilly entered into an exclusive global licensing and research collaboration agreement in March 2020 , under which Sitryx received an upfront payment of $50 million and Lilly made a $10 million equity investment in the Company.
  • Sitryx is using the proceeds to advance its proprietary pipeline of immunometabolism-targeting therapies into clinical development.

AusperBio Welcomes Dr. Will Wei as Head of CMC

Retrieved on: 
Wednesday, January 3, 2024

"We are excited to welcome Dr. Wei to AusperBio's leadership team at this pivotal time for the company," said Dr. Guofeng Cheng, chief executive officer.

Key Points: 
  • "We are excited to welcome Dr. Wei to AusperBio's leadership team at this pivotal time for the company," said Dr. Guofeng Cheng, chief executive officer.
  • "Will's depth and breadth of experience in end-to-end CMC operations, strategic insight will be instrumental in executing our plans, propelling our pipeline, and navigating the dynamic landscape of drug development."
  • Bringing over two decades of outstanding leadership in the biotech and pharmaceutical industry, Dr. Wei has excelled across critical domains in drug development.
  • Dr. Wei earned his Ph.D. in the Department of Organic Chemistry at the University of Lausanne in Switzerland and completed his postdoctoral training at The Scripps Research Institute.

Brii Biosciences Appoints Dr. Brian Alvin Johns as Chief Scientific Officer

Retrieved on: 
Wednesday, January 3, 2024

Dr. Johns will oversee the discovery programs at Brii Bio and set the company's future pipeline strategy and priority.

Key Points: 
  • Dr. Johns will oversee the discovery programs at Brii Bio and set the company's future pipeline strategy and priority.
  • "I am thrilled to reunite with Brian as our Chief Scientific Officer," said Zhi Hong, Ph.D., Chairman and Chief Executive Officer of Brii Bio.
  • Prior to joining Brii Bio, Dr. Johns served as the Chief Scientific Officer at HemoShear Therapeutics, Inc., where he led his team to novel targets and platforms in various disease areas.
  • "I am excited to join Brii Biosciences and contribute to the development of transformative therapies against infectious diseases," said Dr. Brian A. Johns.

Epigenetic Therapeutics Global Markets Research 2023-2028 Featuring Major Players - AstraZeneca, Bristol-Myers Squibb, GSK, Ipsen, Seagen, and Incyte - ResearchAndMarkets.com

Retrieved on: 
Tuesday, January 2, 2024

The global epigenetic therapeutics market was valued at $6.4 billion in 2022.

Key Points: 
  • The global epigenetic therapeutics market was valued at $6.4 billion in 2022.
  • Technological innovations in epigenetic drug discovery and development are driving increased use of epigenetic therapeutics, which also is pushing market growth.
  • This report is a comprehensive study of the global market for epigenetic therapeutics.
  • This report examines the factors driving growth in the epigenetic drugs market, and it reviews major players, established companies and new entrants.

Spero Therapeutics Announces First Patient, First Visit for Phase 3 PIVOT-PO Trial Evaluating Tebipenem HBr in Complicated Urinary Tract Infections

Retrieved on: 
Tuesday, January 2, 2024

Spero is entitled to receive $95 million in development milestone payments from GSK, which is payable in four equal installments over two years.

Key Points: 
  • Spero is entitled to receive $95 million in development milestone payments from GSK, which is payable in four equal installments over two years.
  • “First patient visit, in the PIVOT-PO Phase 3 clinical trial, is an important milestone in our tebipenem HBr program,” said Sath Shukla, President and CEO of Spero Therapeutics.
  • "We are developing Tebipenem HBr to potentially be the first oral broad-spectrum carbapenem in the U.S. for use in patients with cUTI.
  • The primary efficacy endpoint will be overall response (composite of clinical cure plus microbiological eradication) at the test-of-cure visit.

Cellectis Reports Results from Shareholders Meeting Held on December 22, 2023

Retrieved on: 
Friday, December 22, 2023

At the meeting, resolutions 1 through 5 as well as resolutions 7 and 8 were adopted and resolution 6 was rejected, consistent with the recommendations of the board of directors.

Key Points: 
  • At the meeting, resolutions 1 through 5 as well as resolutions 7 and 8 were adopted and resolution 6 was rejected, consistent with the recommendations of the board of directors.
  • The Company’s shareholders also approved the appointments of Mr. Marc Dunoyer and Dr. Tyrell Rivers as directors of the Cellectis board of directors, which appointment remains subject to the completion of the Additional Investment.
  • “We are grateful to our shareholders for supporting the Additional Investment and we are looking forward to welcoming Mr. Dunoyer and Dr. Rivers to our board of directors.
  • The detailed results of the vote and the resolutions are available on Cellectis’ website:

Vertex Announces New Leadership with Three Strategic Appointments in Customer Success and Services, Tax Research and Global Talent

Retrieved on: 
Thursday, December 21, 2023

The wealth of knowledge and skill set they bring will reinforce the company’s strategic focus on customer success, tax research effectiveness and talent development.

Key Points: 
  • The wealth of knowledge and skill set they bring will reinforce the company’s strategic focus on customer success, tax research effectiveness and talent development.
  • With an extensive background in global services, business transformation and innovative enabling technologies, Cunningham will lead the strategy, operations and execution of customer experience and success.
  • As the new SVP of Customer Success and Services, my commitment is to elevate the customer experience strategically and pragmatically,” said Cunningham.
  • “With a keen focus on people-first practices and strategic talent management, I'm eager to contribute to our global talent ecosystem.

SCYX STOCK ALERT: Robbins LLP Reminds Investors of the Upcoming Lead Plaintiff Deadline in the Class Action Against Scynexis, Inc.

Retrieved on: 
Saturday, December 16, 2023

Scynexis is a biotechnology company that is primarily engaged in the development of ibrexafungerp, a broad-spectrum, intravenous (IV)/oral agent for fungal indications.

Key Points: 
  • Scynexis is a biotechnology company that is primarily engaged in the development of ibrexafungerp, a broad-spectrum, intravenous (IV)/oral agent for fungal indications.
  • For more information, submit a form , email Aaron Dumas, Jr., or give us a call at (800) 350-6003.
  • What Now: Similarly situated shareholders may be eligible to participate in the class action against Scynexis, Inc. Shareholders who want to act as lead plaintiff for the class should contact Robbins LLP.
  • A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

IMUNON Appoints Dr. Sebastien Hazard as Chief Medical Officer and Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Monday, December 11, 2023

LAWRENCEVILLE, N.J., Dec. 11, 2023 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing non-viral DNA-mediated immunotherapy and next-generation vaccines, announces the appointment of Sebastien Hazard, M.D. as Chief Medical Officer, effective December 11, 2023. Dr. Hazard brings to IMUNON a strong background in building and leading clinical development organizations, most recently at Bicycle Therapeutics. He will report to IMUNON’s President and Chief Executive Officer, Dr. Corinne Le Goff.

Key Points: 
  • Hazard brings to IMUNON a strong background in building and leading clinical development organizations, most recently at Bicycle Therapeutics.
  • He will report to IMUNON’s President and Chief Executive Officer, Dr. Corinne Le Goff.
  • Each of the Inducement Option and the Restricted Inducement Grant is an inducement material to Dr.
  • Hazard entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).

BioXcel Therapeutics Strengthens Clinical Development Leadership to Advance Late-Stage Programs

Retrieved on: 
Monday, December 11, 2023

NEW HAVEN, Conn., Dec. 11, 2023 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience and immuno-oncology, today announced a key executive promotion and a clinical advisor appointment as part of the Company’s strategic reprioritization focused on the advancement of its late-stage clinical programs and emerging pipeline candidates.

Key Points: 
  • Vincent J. O’Neill, M.D., Senior Vice President and Chief Research & Development Officer of OnkosXcel Therapeutics, has been promoted to Executive Vice President, Chief of Product Development and Medical Officer of BioXcel Therapeutics.
  • Additionally, Rajiv Patni, M.D., has been appointed to the newly created position of Strategic Clinical Advisor to the BioXcel Therapeutics Chief Executive Officer and Board of Directors.
  • Prior to joining BioXcel Therapeutics, Dr. O’Neill held senior leadership roles at several leading global pharmaceutical companies, including Sanofi, Genentech, and GlaxoSmithKline.
  • “I look forward to working with the BioXcel leadership team in continuing to address the unmet medical needs of patients and caregivers and advance the Company’s product-development goals.”